Q2 EPS Estimate for Eledon Pharmaceuticals Lifted by Analyst

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Leerink Partnrs increased their Q2 2025 earnings per share estimates for shares of Eledon Pharmaceuticals in a note issued to investors on Wednesday, May 14th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($0.26) per share for the quarter, up from their prior estimate of ($0.29). The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. Leerink Partnrs also issued estimates for Eledon Pharmaceuticals’ Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($0.87) EPS, FY2026 earnings at ($1.00) EPS, FY2027 earnings at ($1.25) EPS, FY2028 earnings at ($1.19) EPS and FY2029 earnings at ($0.50) EPS.

Separately, Guggenheim initiated coverage on Eledon Pharmaceuticals in a research note on Tuesday, January 28th. They issued a “buy” rating and a $9.00 target price on the stock.

Eledon Pharmaceuticals Stock Performance

ELDN stock opened at $2.87 on Monday. Eledon Pharmaceuticals has a 1 year low of $2.30 and a 1 year high of $5.54. The stock’s 50 day moving average price is $3.17 and its 200 day moving average price is $3.94. The firm has a market cap of $171.86 million, a P/E ratio of -1.43 and a beta of 0.08.

Eledon Pharmaceuticals (NASDAQ:ELDN) last posted its earnings results on Wednesday, May 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.20.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Zimmer Partners LP raised its holdings in Eledon Pharmaceuticals by 0.7% in the 1st quarter. Zimmer Partners LP now owns 754,970 shares of the company’s stock valued at $2,559,000 after acquiring an additional 4,970 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in Eledon Pharmaceuticals by 418.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,944 shares of the company’s stock valued at $33,000 after acquiring an additional 6,412 shares during the last quarter. CW Advisors LLC acquired a new position in Eledon Pharmaceuticals in the 1st quarter valued at $34,000. Renaissance Technologies LLC raised its holdings in Eledon Pharmaceuticals by 8.3% in the 4th quarter. Renaissance Technologies LLC now owns 147,173 shares of the company’s stock valued at $606,000 after acquiring an additional 11,300 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in Eledon Pharmaceuticals in the 1st quarter valued at $41,000. 56.77% of the stock is currently owned by institutional investors and hedge funds.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).